3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Zacks Investment Research highlights Exelixis (EXEL) as a strong growth stock, citing its favorable Growth Score of A and Zacks Rank #2 (Buy). Exelixis is projected to have EPS growth of 28.6% this year, significantly above the industry average of 18.9%, and boasts a year-over-year cash flow growth of 135.6%, outperforming its peers; additionally, current-year earnings estimates have surged 12.9% over the past month, suggesting a positive outlook.

Analysis

Exelixis (EXEL) presents a compelling growth narrative, according to a Zacks Investment Research report, underscored by its "A" Growth Score and #2 (Buy) Zacks Rank. The drug developer is projected to achieve significant earnings per share (EPS) growth of 28.6% this year, substantially outpacing the industry average forecast of 18.9%; this projection follows a historical EPS growth rate of 28.3%. Furthermore, Exelixis demonstrates robust financial health through its cash flow dynamics: its year-over-year cash flow growth stands at an impressive 135.6%, starkly contrasting with the industry's average decline of -4.7%. Over a 3-5 year period, the company's annualized cash flow growth rate of 10.8% also surpasses the industry's 3.6%. Reinforcing this positive outlook, the Zacks Consensus Estimate for Exelixis's current-year earnings has seen a notable upward revision of 12.9% in the past month, a factor empirically linked to near-term stock price movements. The combination of these strong fundamental indicators, particularly the high Growth Score and Buy rating, suggests potential for market outperformance, consistent with Zacks' research on such profiles.

Key Decisions for Investors

• Investors seeking growth exposure should consider Exelixis, given its projected 28.6% EPS growth and robust 135.6% year-over-year cash flow growth, both significantly exceeding industry averages.
• The stock's Zacks Rank #2 (Buy) and Growth Score of A, coupled with a 12.9% upward revision in current-year earnings estimates, signal strong near-term potential according to the Zacks methodology, which historically correlates such profiles with market-beating returns.
• While current fundamentals and proprietary ratings are positive, investors should remain cognizant of the inherent risks and volatility typically associated with growth-focused drug development companies and continue to monitor earnings execution.